IL1B and migraine disorder: A network pharmacology analysis showed that the major anti-migraine targets for YNT constituents were 5-HT, NF-κB, CGRP, nociceptive factors, and inflammation. The in vivo study revealed that YNT could elevate 5-HT expression and decrease NF-κB, CGRP, IL-1β, and c-fos. YNT inhibited LPS-induced inflammation through NF-κB in BV2 cells.